Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Acting as GLP-1R agonists (GLP-1RAs), the drugs promote feelings of satiety and fullness, aiding weight loss among patients who are overweight or obese. Aside from their success for type 2 diabetes ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...